Mesa Laboratories reports increase in revenue

Monday, February 14, 2011

Mesa Laboratories, Inc. (Lakewood) reported a 44 percent increase in revenue and a 19 percent increase in non-GAAP(1) net income for the fiscal third quarter ended December 31, 2010.  During the quarter. Mesa Laboratories completed the acquisition of Apex Laboratories.   

CBSA Launches 2011 Symposium Series with "Biotech & Pharma" Session

Monday, February 14, 2011

Denver, CO – February 14, 2011 – The Colorado BioScience Association (CBSA) is launching its 2011 Symposium Series Thursday, February 17, with the session, "Biotech & Pharma," 1‐7 p.m., at the Grand Hyatt Denver, 1750 Welton Street. The announcement is made by Holli Baumunk, CBSA President & CEO, who says the CBSA's new Symposium Series is being held quarterly this year, with each program focusing intently for a half day on matters of key interest to the state's Bioscience Industry. Upcoming symposiums are planned for June 9 covering Science Investment Opportunities & Options; August 11, Regulatory & Reimbursement Issues; and November 10, Medical Device & Diagnostic Development. 

Medical device makers oppose manufacturing tax

Friday, February 11, 2011

Denver Business Journal - by Greg Avery
Colorado’s medical device makers are rallying behind federal legislation to repeal a tax on their sales that’s predicted to raise $20 billion for overhauling the nation’s health care. 

Democrats: Prove that incentives create jobs

Friday, February 11, 2011

Denver Business Journal - by Ed Sealover
Last year, Statehouse Democrats pushed through cuts in the number of tax credits given to businesses, raising $140 million in new revenue for Colorado. 

miRagen Therapeutics at Keystone Symposia

Friday, February 11, 2011

miRagen Therapeutics, Inc announced that its Co-Founder/Chief Scientific Advisor, Eric N. Olson, Ph.D., and scientific Co-Founder/Director of Biology, Eva van Rooij, Ph.D., are serving as Scientific Organizers as well as presenters at the first Keystone Symposia on Molecular and Cellular Biology conference focused on MicroRNAs and Human Disease. The conference will take place February 11-16, 2011, in Banff, Alberta, Canada.   

Corgenix Medical will highlight AspirinWorks

Wednesday, February 09, 2011

During the conference Pri-Med South 2011, Corgenix Medical Corp. (Denver) will highlight its AspirinWorks® Test for aspirin effect in booth No. 902 at the Broward County Convention Center if Fort Lauderdale, FL.   AspirinWorks is a simple, non-invasive lab test performed on a urine specimen. It is the only FDA-cleared test that helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring the urine levels of 11-dehydro thromboxane B2 (11-dhTxB2), a metabolite of thromboxane, the target of aspirin therapy. Individuals with high levels of 11-dhTxB2 are at increased risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.  

OnBioVC Trend Analysis

Tuesday, February 08, 2011

Bioscience VC, M&A and IPO Overview 

Lung Cancer Prevention Grant Program

Monday, February 07, 2011

The University of Colorado Denver Office of the Vice Chancellor for Research  

Sharklet on CBS Sunday Morning

Sunday, February 06, 2011

How Shark Skin May Help Save Lives
David Pogue Looks at How a Material That Prevents Bacterial Growth Was Inspired by the Most Feared Predator of the Sea 

Colorado’s Bioscience Discovery Evaluation Grant Program Creates 598 New Jobs in the State, with Payroll Exceeding $44 million

Friday, February 04, 2011

Denver - The Colorado BioScience Association (CBSA) and The Colorado Office of Economic Development and International Trade (OEDIT) have jointly released results of the Bioscience Discovery Evaluation Grant Program (BDEGP) at the CBSA's Third Annual "Bioscience Day at the Capitol" event. The announcement is made by Holli Baumunk, CBSA President & CEO, who says the BDEGP has more than met expectations since its inception in 2006, providing the state a significant return on investment.